Must have platelet count ? 100 x 10^9/L within 14 days prior to randomization. Must not have required transfusion of platelets within 1 week of baseline platelet assessment.Xx_NEWLINE_xXPlatelet count < 75 × 10^3/?LXx_NEWLINE_xXPlatelet count >= 100 X 10^9/L, within 28 days prior to administration of study treatmentXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L measured within 28 days prior to randomizationXx_NEWLINE_xXPlatelet count >= 50 x 10^9/LXx_NEWLINE_xXRE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Platelet count >= 50 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L, measured within 28 days prior to administration of study treatmentXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xX* Platelets >= 100 x 10^9 cells/ L (unsupported, defined as no platelet transfusion within 7 days)Xx_NEWLINE_xXPlatelet count ? 100 × 10e3/µLXx_NEWLINE_xXPlatelet count < 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count > 100 x 103/µLXx_NEWLINE_xXPlatelet >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 75 x 10^9/LXx_NEWLINE_xXPlatelet counts >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count > 50 k/mcLXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count ? 100 × 10^9/LXx_NEWLINE_xXPlatelet count >= 75 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 X 10^9/L within 14 days of starting cycle 1 day 1 treatmentXx_NEWLINE_xXPlatelet count >= 50 x 10^9/LXx_NEWLINE_xXPlatelet count >= 75,000/uL (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to enrollment) for subjects without bone marrow involvementXx_NEWLINE_xXPlatelet count of ?75000/µL.Xx_NEWLINE_xXPlatelet count >= 75 x 10^9/LXx_NEWLINE_xXPlatelet count >= 75 × 10^9/L or >= 50× 10^9/L if there is lymphoma involvement in the bone marrow, independent of platelet transfusionXx_NEWLINE_xXScreening platelet count should be independent of platelet transfusions for at least 2 weeks.Xx_NEWLINE_xXPlatelet count greater than or equal to 100 x 10 to the ninth/LiterXx_NEWLINE_xXHematologic: Platelets ?100 x 10(9)/L; ANC ?1.5 x 10(9)/L (without platelet transfusion or growth factors within the 7 days prior to the screening laboratory assessment)Xx_NEWLINE_xXHave a platelet count ?75 × 109/L.Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXWithin 10 (except as noted) days of planned treatment initiation: Platelet count >= 100 × 10^9/L (>= 100,000 per mm^3)Xx_NEWLINE_xXPlatelet counts > 100 x 10^9/LXx_NEWLINE_xXObtained within 28 days prior to registration: Platelet count >= 60 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L performed within 30 days prior to the date of registrationXx_NEWLINE_xXand platelet count ? 100 × 109/LXx_NEWLINE_xXParticipants with CR with incomplete count recovery (CRp or CRi) are allowed. Incomplete platelet recovery (CRp) is defined as CR with platelet count < 100 x 109/L. Incomplete blood count recovery (CRi) is defined as CR with residual neutropenia < 1 x 109/L with or without complete platelet recovery. Red blood cell count (RBC) and platelet transfusion independence is not required.Xx_NEWLINE_xXPlatelet count < 100 x 109/L.Xx_NEWLINE_xXPlatelet counts >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count ?75 x 10?/L (Parts 1 and 2), ?100 x 10?/L (Part 3)Xx_NEWLINE_xXPlatelet count >= 100 K/uL within 14 days prior to start of protocol therapy.Xx_NEWLINE_xXPlatelet count >= 75 x 10^9/L (transfusion independent for > 7 days)Xx_NEWLINE_xXPlatelet count < 100 x 10 (exp9)/LXx_NEWLINE_xXPlatelets >= 100 x 10^9 (without platelet transfusion)Xx_NEWLINE_xXPlatelet count ?100×10?/L, with no platelet transfusions within the prior 14 days.Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x10^9/LXx_NEWLINE_xXPlatelet count ?100 x 109/L;Xx_NEWLINE_xXPlatelet count > 100000 /mm^3Xx_NEWLINE_xXPlatelet count >= 80 x 10^9/LXx_NEWLINE_xXPlatelet count >= 25 x 10^9/L (obtained =< 14 days prior to registration)Xx_NEWLINE_xXANC < 0.5 x 10^9/L or platelet count < 50 x 10^9/L unless due to disease involvement in the bone marrow.Xx_NEWLINE_xXPlatelet count ? 100 x 10?/L.Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count of >= 50 x 10^9/LXx_NEWLINE_xXPlatelet count > 100 x 10^9/lXx_NEWLINE_xXPlatelet count >= 75 x 10^9/LXx_NEWLINE_xXPlatelet count < 100 x 10^9/LXx_NEWLINE_xXWithin 14 days of randomization: Platelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 × 10^9/L.Xx_NEWLINE_xXObtained ? 14 days prior to registration: Platelet count ? 75000/mm^3; Note: Platelet transfusion is not allowed ? 3 days prior to registrationXx_NEWLINE_xXPlatelet count >= 75×10^9/L.Xx_NEWLINE_xXEvidence of mucosal or internal bleeding and/or are platelet transfusion refractory (i.e. platelet count fails to increase by > 10,000 cells/mm3 after transfusion of an appropriate dose of platelets)Xx_NEWLINE_xXPlatelet count >= 75 x 10^9/LXx_NEWLINE_xXPlatelet count less than 100000/mm^3Xx_NEWLINE_xXPlatelet count >= 120 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (in absence of blood transfusion).Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/L.Xx_NEWLINE_xXPlatelet count >= 75 X 10^9/LXx_NEWLINE_xXPlatelet count <100 x 109/LXx_NEWLINE_xXPlatelet count ?50 × 10^9/L (Grade ?2).Xx_NEWLINE_xXPlatelet count > 100 k/cummXx_NEWLINE_xXPlatelet count ? 100 x 10^9/LXx_NEWLINE_xXPlatelet ? 100 x 10^9/L.Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count > 20 K/uLXx_NEWLINE_xXWithin 4 weeks before enrollment: Platelet count >= 20 x 10^9/LXx_NEWLINE_xXPlatelet count ? 100 × 10^9/LXx_NEWLINE_xXPlatelet count 75 x 10^9/L (75000/L)Xx_NEWLINE_xXPlatelet count >= 100 k/mcl, obtained within 7 days prior to first study treatmentXx_NEWLINE_xXPlatelet (PLT) count > 80 K/uLXx_NEWLINE_xXPlatelet count >= 100 x 10^9 platelets per LXx_NEWLINE_xXPlatelet >= 100 x 10^3/uL within 14 days of registrationXx_NEWLINE_xXPlatelet count ? 100 × 109/LXx_NEWLINE_xXPlatelet count ?100 × 10^9/L (not receiving platelet transfusions within a 7-day period prior to study drug administration).Xx_NEWLINE_xXObtained =< 14 days prior to registration: Platelet count >= 75 x 10^9/L unless the participant has >= 50% bone marrow infiltration in which case a platelet count of >= 50 x 10^9/L is allowedXx_NEWLINE_xXPlatelet count ? 100 × 10^9/LXx_NEWLINE_xXPlatelet count < 35 K/uLXx_NEWLINE_xXPlatelet count >= 150 x 10^9/LXx_NEWLINE_xXWithin 14 days of the first study treatment: Platelet count >= 100 x 10^9/LXx_NEWLINE_xXWithin 14 days prior to registration: Platelet count >= 100 x 10^9/LXx_NEWLINE_xXplatelet count ? 100 x 109/L;Xx_NEWLINE_xXHematologic: ANC 1.5 x 109/L, Hgb ? 9.0 g/dL and platelet count 100 x 109/L (platelet count > 75 x 109/L if documented evidence of bone marrow involvement).Xx_NEWLINE_xXPlatelet count >= 75 x 10^9/LXx_NEWLINE_xXHas a bleeding disorder or a screening platelet count < 100×109/L.Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 75 x 10^9/L, measured within 28 days prior to administration of study treatmentXx_NEWLINE_xXSubjects with a platelet count of at least 100 x 10^9 at the screening visitXx_NEWLINE_xXPlatelet count >= 75000/mcLXx_NEWLINE_xXPlatelet count < 50 × 10^9/L in the 4 weeks before screening or platelet transfusion(s) within 8 weeks before screeningXx_NEWLINE_xXPlatelet count ? 100 x 10 9/LXx_NEWLINE_xXPlatelet count > 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count ?75 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count =< 450,000 x 10^9/LXx_NEWLINE_xXPlatelet count >= 90 x 10^9/LXx_NEWLINE_xXPlatelet count <100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/l at cycle 1 day 1 of TPFXx_NEWLINE_xXPlatelet count >= 75,000/mcL; platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollmentXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count =< 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 50 x 10^9/L (without use of growth factors [ie., interleukin 11 (oprelvekin)]) (within 14 days prior to registration)Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet > 20 x 10^9/L without platelet transfusion within 1 weekXx_NEWLINE_xXPlatelet count of >= 100 k/mL independent of transfusion and/or growth factors within 3 months prior to randomizationXx_NEWLINE_xXPlatelet count ? 100 x 109/LXx_NEWLINE_xXPlatelet count < 100 x 10^9/LXx_NEWLINE_xXPlatelet count of greater than 20,000/mul, with no platelet transfusion in 2 weeks prior to registration; this criteria is waived if the thrombocytopenia is due to bone marrow involvement with the diseaseXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXBone marrow reserve consistent with: platelet count >= 100 x 109/L values must be obtained without the need for myeloid growth factor support, platelet or PRBC transfusion support within 14 daysXx_NEWLINE_xXPlatelet count >= 75000/mm^3Xx_NEWLINE_xXPlatelet count ?150 x 109/L;Xx_NEWLINE_xXPlatelet count > 75K/uLXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet (PLT) >= 100 K/CUMMXx_NEWLINE_xXPlatelet count greater than or equal to 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (measured within 28 days prior to administration of study treatment)Xx_NEWLINE_xXPlatelet count (Plt) ? 100 x 109/LXx_NEWLINE_xXplatelet count greater than or equal to 75 x 10^9/L.Xx_NEWLINE_xXPlatelet count of < 100 x 10^9/L; platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollmentXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 75 x 10^9/LXx_NEWLINE_xXPlatelet (PLT) > 99 x 10^9/LXx_NEWLINE_xXPlatelet > 100Xx_NEWLINE_xXHas hemoglobin ? 10 g/dL, ANC ? 1.5 × 109/L, and platelet count ? 100 × 109/LXx_NEWLINE_xXPlatelet count >= 40 x 10^3/mm^3 (may be post-transfusion)Xx_NEWLINE_xXPlatelet count =< 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count 50,000/uL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment. Exception: Patients that are platelet dependent due to previous extensive treatment- e.g. - MIBG therapy).Xx_NEWLINE_xXPlatelet count ? 75 × 109/LXx_NEWLINE_xXPlatelet count > or = 30 x 10^9/LXx_NEWLINE_xXPlatelet count >= 75 × 10^9/L (>= 30 × 10^9/L if myeloma involvement in the bone marrow is > 50%)Xx_NEWLINE_xXPlatelet count (PLT) >= 75 x 10^9/L; PLT count less than 100 x 10^9/L if cytopenia is due to extensive bone marrow involvement of disease as determined by the treating physicianXx_NEWLINE_xXPlatelet count >= 50 x 10^9/L (>= 20 x 10^9/L if lymphoma involvement in the pre-treatment bone marrow is found) within 14 days prior to starting therapyXx_NEWLINE_xXPlatelet count < 70Xx_NEWLINE_xXPlatelet count >= 75.0 x 10^9/L or =< 75.0 x 10^9/L but >= 50.0 x 10^9/L due to > 30% marrow involvement\r\n* Patients who entered the trial prior to June 4, 2014 were restricted to > 50% marrow involvementXx_NEWLINE_xXScreening platelet count should be independent of platelet transfusions for at least 1 weekXx_NEWLINE_xXPlatelet count >= 50 x 10^9 /uL without platelet transfusionsXx_NEWLINE_xXPlatelet count of >= 100 x 10^9/L (performed within 14 days prior to registration)Xx_NEWLINE_xXPlatelet count < 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 80 K/uL (in the expansion cohorts, if thrombocytopenia is due to bone marrow involvement platelet count must be >= 50 K/uL), without platelet transfusions for 1 weekXx_NEWLINE_xXPlatelet count < 75 x 10^9/LXx_NEWLINE_xXPlatelet count >= 60 x 10^9/LXx_NEWLINE_xXPlatelet count >= 20 x 10^9/L and able to achieve a platelet count of >= 50 x 10^9/L with transfusion supportXx_NEWLINE_xXIn patients 18-60 years of age, moderately severe aplastic anemia is defined as having at least one of the following:\r\n* Platelet count < 20 x 10^9/L\r\n* ANC < 5 x 10^8/L\r\n* Hgb < 8 g/dLXx_NEWLINE_xXPlatelet ?100 x 10^9/L, without transfusion within 7 days preceding the lab assessmentXx_NEWLINE_xXPlatelet count of >100 x109/LXx_NEWLINE_xXPlatelet count ?100 × 10^9/L (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to study drug administration)Xx_NEWLINE_xXPlatelet count (>=) 10*10^9 per liter (L) (prior platelet transfusion is permitted)Xx_NEWLINE_xXplatelet count ?100 x 109/LXx_NEWLINE_xXPlatelet count < 75x10^9 /LXx_NEWLINE_xXPlatelet count ?100×10^9/L.Xx_NEWLINE_xXPlatelet count < 75 x 109/LXx_NEWLINE_xXPlatelet count 100000/?lXx_NEWLINE_xXPlatelet count ? 100 x 109/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/lXx_NEWLINE_xXPlatelet count ?10,000 ?L with or without transfusion supportXx_NEWLINE_xXBone Marrow Reserve: absolute neutrophil count ? 1.5 x 10^9/L; platelet count ? 100 x 10^9/L; hemoglobin ? 9.0 g/dL. Must not have required blood transfusion within 1 week of baseline blood count assessment.Xx_NEWLINE_xXORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Platelet count > 100,000 x 10^9/mLXx_NEWLINE_xXHPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Platelet count > 100,000 x 10^9/mLXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L within 28 days prior to administration of study treatment.Xx_NEWLINE_xXWithin 28 days prior to administration of study treatment: Platelet count ? 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 75 mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 7 days before study enrollmentXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXWithin 14 days prior to first dose of study drug treatment: Platelet count >= 100 x 109/LXx_NEWLINE_xXWithin 10 days of treatment initiation: platelet count >= 100 x 109/LXx_NEWLINE_xXPlatelets >= 100 x 10^9 cells/L (unsupported, defined as no platelet transfusion within 7 days)Xx_NEWLINE_xXPlatelet count < 75 × 10^9/L.Xx_NEWLINE_xXWithin 14 days prior to registration: Platelet count >= 100 x 10^9/LXx_NEWLINE_xXMeasured within 28 days prior to administration of study treatment: Platelet count >= 100 x 10^9/LXx_NEWLINE_xXObtained within 30 days prior to registration: Platelet > 100 kXx_NEWLINE_xXPlatelet count >= 75×10^9/L within 2 weeks before baselineXx_NEWLINE_xXPlatelet count >= 75000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/uL (transfusion independent)\r\n* If the ANC and/or platelet count are not adequate, but due to bone marrow metastatic disease, these criteria will be waivedXx_NEWLINE_xXFor patients with solid tumors and known bone marrow metastatic disease: platelet count >= 75,000/uL (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (no transfusion allowed within 2 weeks)Xx_NEWLINE_xXPlatelets >= 70 x 10^9/L without platelet transfusion 7 days prior to study entryXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L, measured within 28 days prior to administration of study treatmentXx_NEWLINE_xXPlatelet >= 50 x 10^9/lXx_NEWLINE_xXPlatelet count > 50 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count:Xx_NEWLINE_xXPlatelet count < 50 K/mcL at time of enrollmentXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count ? 100 x 10^9/L.Xx_NEWLINE_xXANC ? 0.5 x 10^9/L or platelet count ? 50 x 10^9/L unless due to disease involvement in the bone marrow.Xx_NEWLINE_xXPlatelet count >= 100,000ulXx_NEWLINE_xXWithin 56 days prior to randomization: Platelet count >= 50,000/mcL (50 x 10^9/L) without platelet transfusionXx_NEWLINE_xXPlatelet count of ?75000/?L.Xx_NEWLINE_xXPlatelets ? 100 x 10^9/L; patients with hepatocellular carcinoma may enroll provided they have a platelet count ? 75 x 10^9/L.Xx_NEWLINE_xXplatelet count ?90 × 109/LXx_NEWLINE_xXPlatelet count < 50 x 10e9/L, ORXx_NEWLINE_xXPlatelet count >= 75 x 10^9/LXx_NEWLINE_xXPlatelet count of > 50 x 10? or > 50% prothrombin activityXx_NEWLINE_xXPlatelet count >= 75 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L without transfusion, obtained within 14 days prior to initiation of study treatmentXx_NEWLINE_xXPlatelet count ? 75 × 109/L.Xx_NEWLINE_xXPlatelet count > 75 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count ?100×10^9/LXx_NEWLINE_xXPlatelets ? 100 x 10^9/L; patients with hepatocellular carcinoma may enroll provided they have a platelet count ? 75 x 10^9/L.Xx_NEWLINE_xXPlatelet count ?100 x 109/LXx_NEWLINE_xXB-Platelet count ?150 x10e9/LXx_NEWLINE_xXPlatelet count greater than or equal to 100 x 109/LXx_NEWLINE_xXPlatelet count ? 7.5 x 104 /mm3Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet Count ? 50 x 10^9/L (? 100 x 10^9/L if aspartate aminotransferase [AST] or alanine aminotransferase [ALT] is ? 2 x the upper limit of the normal range [ULN]) in the absence of platelet transfusion(s) or thrombopoietin mimetics in the prior 7 daysXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count greater than or equal to 75 X 10^9/LXx_NEWLINE_xXPlatelet count >= 50 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count > 25 K/uLXx_NEWLINE_xXPlatelet count ?100×109/L and no platelet transfusions during the prior 14 daysXx_NEWLINE_xXPlatelet count ? 100 × 10e3/µLXx_NEWLINE_xXPlatelet count < 75 x 10^9/LXx_NEWLINE_xXAdequate hematology laboratory results (absolute neutrophil count ? 1.5 x 10^9/L, platelet count ? 75 x 10^9/L, hemoglobin ? 10.0 g/dL).Xx_NEWLINE_xXPlatelet count >= 50 x 10^9/LXx_NEWLINE_xXPatient has a bleeding disorder or a screening platelet count <100×109/L.Xx_NEWLINE_xXPlatelet count > 100 x 10^9/L (within 7 days prior to registration); orXx_NEWLINE_xXPlatelet count >= 50 × 10^9/LXx_NEWLINE_xXPlatelet count ? 100 × 109/LXx_NEWLINE_xXand platelet count ? 100 × 10^9/LXx_NEWLINE_xXPlatelet count >= 80 K/u (in the Phase IIa portion, if thrombocytopenia is due to bone marrow involvement platelet count must be >= 50 K/uL)Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count ?100 x10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L without platelet transfusion within 7 daysXx_NEWLINE_xXPlatelets >= 100 x 10^9/L and no platelet transfusion within the past 14 days prior to study registrationXx_NEWLINE_xXPlatelet count >= 40 x 10^3/mm^3 (may be post-transfusion)Xx_NEWLINE_xXPlatelet count =< 80 x 10^9/LXx_NEWLINE_xXPlatelet count >= 75,000/uL for patients in whom < 50% of bone marrow nucleated cells are plasma cells; or a platelet count >= 50,000/uL for patients in whom >= 50% of bone marrow nucleated cells are plasma cells; platelet transfusions are not allowed within 3 days of last platelet assessment to confirm eligibilityXx_NEWLINE_xXPlatelet count >= 75 x 10^9/LXx_NEWLINE_xXPlatelet count > 100 x 10^9/L (30 x 10^9/L if myeloma involvement in the bone marrow aspirate is > 50%) within 30 days prior to cycle 1 day 1; subjects may receive platelet transfusions within institutional guidelinesXx_NEWLINE_xXPlatelet count of ?100 x 109/L.Xx_NEWLINE_xXAt least 4 weeks (28 days) prior to registration: Platelet count >= 100 x 10^9/L (no transfusion allowed within 2 weeks)Xx_NEWLINE_xXPlatelet count =< 100 x 10^9/L at baselineXx_NEWLINE_xXPlatelet count ? 10,000 ?L with or without transfusion supportXx_NEWLINE_xXPlatelet count >= 100 x 10^3/uLXx_NEWLINE_xXPlatelet count <100 x 109/LXx_NEWLINE_xXPlatelet counts ?75 x 10^9/LXx_NEWLINE_xXPlatelet count >= 50 x 10^9/L (>= 30 x 10^9/L if myeloma involvement in the bone marrow is > 50%) within 14 days prior to initial treatment (subjects may be receiving platelet transfusions in accordance with institutional guidelines)Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/L.Xx_NEWLINE_xXPlatelet count >= 100 K/mcLXx_NEWLINE_xXPlatelet count >= 50 x 10^9/LXx_NEWLINE_xXPlatelet count > 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 60 x 10^9/LXx_NEWLINE_xXPlatelet count <100x10^9/LXx_NEWLINE_xXThrombocytopenia (platelet count < 100 x 10^3/uL)Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100000/mm^3 (within 16 days before starting therapy)Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/L and =< 850 x 10^9/LXx_NEWLINE_xXPlatelet count >= 75 x 10^9/L; screening platelet count should be independent of platelet transfusions for at least 2 weeksXx_NEWLINE_xXPlatelet count >= 70 K/uL, if thrombocytopenia is due to bone marrow involvement platelet count must be >= 50 K/uLXx_NEWLINE_xXPlatelet count ? 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/lXx_NEWLINE_xXPatients who are platelet refractory prior to initiation of protocol therapy; platelet refractoriness is defined by platelet count < 50 K when platelet count is obtained 1 hour post platelet transfusionXx_NEWLINE_xXPlatelet count ? 75 × 109/L without previous transfusion within 10 days of first study drug administrationXx_NEWLINE_xXPatient has a platelet count of < 50 within 5 days before enrollmentXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXDONOR: Complete blood count (CBC)/diff/platelet count near normal limits (+/- 10%)Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXHas platelet count <75x10^9/L within 14 days before enrollment.Xx_NEWLINE_xXPlatelets >= 75 x 10^9/L; if the bone marrow contains >= 50% plasma cells, a platelet count of >= 50 x 10^9/L is allowedXx_NEWLINE_xXPlatelet count < 100x10 ^9/L at screening or at Study Day 1.Xx_NEWLINE_xXThe mean of the two platelet counts taken within 1 month prior to dosing must be =< 50 x 10^9/L; platelets counts must reflect pre-transfusion trough results or be obtained no sooner than 1 week after platelet transfusion to assure stable baseline platelet count; the platelet count obtained should be outside the expected nadir of prior therapiesXx_NEWLINE_xXPlatelets >= 100 x 10^9/L (must be independent of platelet transfusion)Xx_NEWLINE_xXPlatelet count >= 50 x 109/LXx_NEWLINE_xXPlatelet count > 75000/mm^3Xx_NEWLINE_xXPlatelet count ? 75 x 109/LXx_NEWLINE_xXPlatelet count > 400 × 10^9/L and WBC count < 2.5 × 10^9/L or hemoglobin < 10 g/dL at any dose of hydroxyurea.Xx_NEWLINE_xXPlatelet count > 650 × 10^9/L at screening.Xx_NEWLINE_xXAdequate hematological function defined by white blood cell (WBC) count ?3 × 10^9/L; absolute neutrophil count (ANC) ?1.5 × 10^9/L; lymphocyte count ?0.5 × 10^9/L; platelet count ?100 × 10^9/L; and hemoglobin ?9 g/dL (may have been transfused).Xx_NEWLINE_xXAdequate hematological function, defined as WBC ?3 × 10^9/L; ANC ?1.5 × 10^9/L; lymphocyte count ?0.5 × 10^9/L; platelet count ?100 × 10^9/L; and hemoglobin ?9 g/dL (may have been transfused).Xx_NEWLINE_xXPlatelet >= 100 x 10^9/L (> 100,00 per mm^3), obtained within 14 days prior to first treatmentXx_NEWLINE_xXPlatelet count ? 100 × 109/LXx_NEWLINE_xXPlatelet count ?100 x 109/L,Xx_NEWLINE_xXPlatelet count >= 75 x 10^9/L; platelet support is permitted within 14 days although platelet transfusions to help participants meet eligibility criteria are not allowed within 72 hours (3 days) prior to the blood sample to confirm protocol eligibility, within 14 days prior to registrationXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPatients >= 35 days post HCT with platelet count =< 20 x 10^9/l sustained for 7 days or patients are platelet transfusion dependentXx_NEWLINE_xXPlatelet count <50,000/?L (50 X 109/L)Xx_NEWLINE_xXPlatelet count >= 100 x 10^9 cells/LXx_NEWLINE_xXPatient has a platelet count of < 100 x 10^9/L.Xx_NEWLINE_xXPlatelet count ? 7.5 x 104 /mm3Xx_NEWLINE_xXPlatelet count ?75 × 109/LXx_NEWLINE_xXPlatelet count >50 x 10(9)/L with no evidence of bleeding and not requiring platelet transfusions;Xx_NEWLINE_xXPlatelet count ? 7.5 x 10^4/mm^3Xx_NEWLINE_xXThrombocytopenia with platelet count < 50x10e9/L or more than 50% decrease in platelet count from the highest value achieved after transplantXx_NEWLINE_xXPlatelet count ?75 × 109/LXx_NEWLINE_xXThrombocytopenia (platelet count < 100 x 10^3/uL)Xx_NEWLINE_xXPlatelet count >10,000 cells/mm3 (10 x 109/L)Xx_NEWLINE_xXPlatelet count >= 100000/mm^3Xx_NEWLINE_xXPlatelet count ? 100 x 10^9/LXx_NEWLINE_xXPlatelet count ? 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 120 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100000/mm^3Xx_NEWLINE_xXAt least one platelet count < 75 Gi/LXx_NEWLINE_xXPlatelet count > 100 x 109/LXx_NEWLINE_xXNormal platelet count and coagulation profileXx_NEWLINE_xXPlatelet count < 75 x 109/LXx_NEWLINE_xXPlatelet count ?50 x 10E3/µLXx_NEWLINE_xXPlatelet count >= 100 x 10^9 LXx_NEWLINE_xXPatients with evidence of mucosal or internal bleeding and/or platelet transfusion refractory (i.e., unable to maintain a platelet count ? 50,000 cells/dL).Xx_NEWLINE_xXPlatelet count of >= 100 x 10^9/LXx_NEWLINE_xXDONOR: Complete blood count (CBC)/diff/platelet count near normal limits (plus/minus 10%)Xx_NEWLINE_xXWithin 14 days prior to first study treatment: Platelet count >= 100,000/10^9 dLXx_NEWLINE_xXPlatelet count >=100*10^9/L.Xx_NEWLINE_xXPlatelet count >= 50 x 10^3/mm^3Xx_NEWLINE_xXPlatelet Count ? 50 x 10^9/LXx_NEWLINE_xXPlatelet count ?100×10E9/L.Xx_NEWLINE_xXPlatelet >= 50 x 10^9/L (without transfusion)Xx_NEWLINE_xXPlatelet count < 50 x 10^9/LXx_NEWLINE_xXPlatelet count >= 70 K/mm^3 un-transfusedXx_NEWLINE_xXPlatelet count <100 x 10^9/L.Xx_NEWLINE_xXPlatelet count >= 130/mm^3Xx_NEWLINE_xXPlatelet count ? 75 x 103 /µL, andXx_NEWLINE_xXPlatelet count >= 100000/mm^3Xx_NEWLINE_xXPlatelet count ? 100 x 10^9/L within 14 days prior to randomization. Must not have required transfusion within 1 week of baseline platelet assessment.Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXHas adequate bone marrow function, defined as: Platelet count >= 100 X 10*9/L Hemoglobin level >= 9.0 g/dL Absolute neutrophil count >= 1.5 x 10*9/LXx_NEWLINE_xXPlatelet count >= 75 x 10^3/uL obtained at baseline (day 1 of cycle 1, before study drug administration)Xx_NEWLINE_xXPlatelet count at least 100 x 10^9/LXx_NEWLINE_xXPlatelet count ? 100 x 10?/LXx_NEWLINE_xXPlatelet count ? 100 x 109/LXx_NEWLINE_xXPlatelet count of ?100 x 109/L.Xx_NEWLINE_xXPatients must have adequate bone marrow function, defined as an absolute neutrophil count >= 1.5 x 10^9/L and a platelet count >= 100 x 10^9/L.Xx_NEWLINE_xXPlatelet count 75 x 109/L without platelet transfusion within one week. Adequate organ function:Xx_NEWLINE_xX(Untransfused) platelet count >= 50000/uLXx_NEWLINE_xXPlatelet count ?75.0 x 109/LXx_NEWLINE_xXScreening platelet count should be independent of platelet transfusions for at least 2 weeksXx_NEWLINE_xXScreening platelet count >= 50 x 10^9/L independent of platelet transfusions for at least 2 weeksXx_NEWLINE_xXPlatelet count of =< 50 x 10^9/L less than 7 days before enrollment; platelet transfusions are permitted to reach entry criteria but should be discussed on a case-by-case basis with the study principal investigator (PI) and permission will depend on etiology of the thrombocytopenia, if not felt to be due to MMXx_NEWLINE_xXUntransfused platelet count >= 75000/uLXx_NEWLINE_xXPlatelet count ? 80 x 109/LXx_NEWLINE_xXPlatelet count ? 100 x 109/LXx_NEWLINE_xXPlatelet count ?50.0 x 109/LXx_NEWLINE_xXPlatelet count >= 100000/mm^3Xx_NEWLINE_xXPlatelet count ? 150 × 10^9/L prior to dosing on Cycle 1 Day 1Xx_NEWLINE_xXPlatelet count ? 100 x 10^9/L;Xx_NEWLINE_xXPlatelet count >= 75 x 10^9/L (platelet transfusions cannot be used within 4 days of first drug administration)Xx_NEWLINE_xXPlatelet count ?75 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count ? 50 × 10^9/L (? 30 × 10^9/L if myeloma involvement in the bone marrow is > 50%) within 21 days prior to randomizationXx_NEWLINE_xXplatelet count >=100*10^9/LXx_NEWLINE_xXUntransfused platelet count < 50,000 cells/µL (50 x 10^9/L)Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 20 x 10^9/L (without transfusion support within 2 weeks of registration)Xx_NEWLINE_xXPlatelet count ? 7.5 × 104/mm3Xx_NEWLINE_xXComplete blood count (CBC), differential and platelet countXx_NEWLINE_xXPlatelet count >= 150 x 10^9/LXx_NEWLINE_xXPatient requiring platelet transfusion threshold of > 20 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count of at least 100 × 109/L, andXx_NEWLINE_xXPlatelet count ?100 × 10^9/LXx_NEWLINE_xXFailure to achieve platelet engraftment (defined as platelet count >= 20 x 10^9/L on 3 consecutive measurements without transfusion for 7 days) by day +28 post UCBTXx_NEWLINE_xXPatients requiring more than one platelet transfusion per dayXx_NEWLINE_xXAnticipated platelet count =< 50 x 10^9/L for >= 5 days within 72 hours of enrollmentXx_NEWLINE_xXSubjects with a platelet count of at least 75 x 10^9/L at the screening visitXx_NEWLINE_xXPlatelet count > 100000 /mm^3Xx_NEWLINE_xXSubjects for whom prophylactic platelet transfusions, at platelet counts >10× 109/L, are anticipated following PBSC transplantXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXSubjects must have a platelet count of >= 30,000 to receive the immunizations; patients requiring platelet transfusions are eligible to enroll and must have a platelet count >= 30,000 within 72 hours prior to their immunization; for subjects < 12 months post-transplant, if a platelet count of >= 75,000 is documented without transfusion support within 14 days of the immunization, then an additional platelet count does not need to be repeated prior to immunization; for subjects 12-23 months post-transplant, if a platelet count of >= 75,000 is documented without transfusion support within 90 days of the immunization, then an additional platelet count does not need to be repeated prior to immunizationXx_NEWLINE_xXPlatelet count: 10-600/uLXx_NEWLINE_xXPlatelet count > 50 x 10^9/LXx_NEWLINE_xXNeutrophil count < 1.5 x 10^9/L or platelet count < 75 x 10^9/LXx_NEWLINE_xXPlatelet count < 100Xx_NEWLINE_xXMeasured within 28 days prior to administration of study treatment: Platelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelets >= 100 x 10^9/L (or platelet count >= 30 x 10^9 cells/L in patients with lymphoma or CLL if bone marrow disease involvement is documented)Xx_NEWLINE_xXPlatelet count of > 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 X 10^9/L w/o blood transfusions for 7 days preceding lab assessment, obtained within 14 days prior to PET scanXx_NEWLINE_xXPlatelet count >= 50/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 7 days before study enrollmentXx_NEWLINE_xXPlatelet dysfunction or platelet count < 100 x 103 cells/mm3Xx_NEWLINE_xXPlatelet count (PLT) > 100 K/uLXx_NEWLINE_xXPlatelet count ?150 x 109/LXx_NEWLINE_xXPlatelet ? 100/mm3Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/L (may have been transfused)Xx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/lXx_NEWLINE_xXPlatelet count >= 75 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count >= 100 x 10^9/LXx_NEWLINE_xXPlatelet count ? 100 x 109/l, hemoglobin ? 9.0 g/dl and ANC ? 1.0 x 109/l.Xx_NEWLINE_xXPlatelet count < 50 x 10^9/LXx_NEWLINE_xXPlatelet count ? 100x10^9/L.Xx_NEWLINE_xX